The poster presentation was given by Dr. Joshua Tobias at the American Association of Cancer Research (AACR) Annual Meeting (April 5-10, 2024; San Diego, CA, USA). Dr. Sharon Yavrom (in the Photo), a representative from the cooperation partner company Imugene Ltd, which has coordinated the Phase Ib and Phase II trial of HER-Vaxx, was also at the poster session.

A manuscript on the significant HER-Vaxx Phase II final results showing the vaccine's safety profile, clinical efficacy in terms of overall survival, progression-free survival, and tumor reduction, which significantly correlated with vaccine-induced immune responses, has now been reviewed for publication in the prestigious AACR journal 'Clinical Cancer Research'.